SPRC SciSparc Ltd.
Price Chart
Executive Summary
SciSparc's majority-owned subsidiary NeuroThera Labs completed the acquisition of a ~54% interest in CliniQuantum Ltd., a private Israeli quantum simulation company, for approximately CAD$9.46M in NeuroThera shares plus up to US$2.5M in earn-out payments. The deal adds a quantum-based clinical trial analytics platform but provides no near-term revenue or pipeline catalyst for SciSparc, which remains a pre-revenue clinical-stage biotech with a $5M market cap.
Actionable Insight
This is a non-cash, subsidiary-level acquisition with no immediate revenue or clinical catalyst for SciSparc. The deal adds speculative quantum analytics IP but does not change SciSparc's cash runway or near-term development timeline. Monitor NeuroThera's TSXV trading for dilution impact and any future CliniQuantum-related milestones. The stock's historical T+20 performance on neutral filings has been deeply negative (-24.5% avg), suggesting limited market enthusiasm for non-catalyst news.
Key Facts
- NeuroThera Labs (TSXV: NTLX), SciSparc's majority-owned subsidiary, acquired ~54% of CliniQuantum Ltd. for 56.6M NeuroThera shares valued at ~CAD$9.46M based on 20-day VWAP.
- Earn-out payments of up to US$2.5M are contingent on patent filings and fundraising milestones over three years.
- CliniQuantum's main asset is an exclusive license to a single US provisional patent application for quantum Monte Carlo methods in clinical trial data analysis.
- The SPA was amended on April 30, 2026 to set a floor price of CAD$0.05 per share for earn-out issuances and to add lock-up arrangements for selling shareholders.
- SciSparc's market cap is ~$5M; the company had only 365,444 ordinary shares outstanding as of Dec 31, 2025 after two reverse splits.
Financial Impact
Consideration of ~CAD$9.46M in NeuroThera shares plus up to US$2.5M in contingent earn-outs. No cash consideration disclosed.
Risk Factors
- Dilution from 56.6M NeuroThera shares issued; SciSparc's indirect ownership stake in NeuroThera may be diluted if NeuroThera issues more shares for earn-outs.
- CliniQuantum is pre-revenue with only a provisional patent application — no guarantee of commercial value or regulatory acceptance of its quantum analytics approach.
- SciSparc's extremely small share count (365K shares) and $5M market cap make the stock highly volatile and susceptible to large percentage moves on low volume.
- Historical calibration shows score-4 to score-6 neutral filings on SPRC have averaged -24.5% at T+20, indicating poor market reception to routine corporate updates.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-065026 |
| Document: ea029361602ex99-1.htm | 0001213900-26-065026 |
| Document: 0001213900-26-065026-index-headers.html | 0001213900-26-065026 |
| Document: 0001213900-26-065026-index.html | 0001213900-26-065026 |
| Document: 0001213900-26-065026.txt | 0001213900-26-065026 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
2d ago
|
6-K
| $11.54 $11.44 | ▼ −0.87% | ▲ +1.73% | $11.44 (−0.87%) |
|
Jun 4, 2026
2d ago
|
Press Release
| $11.54 $11.44 | ▼ −0.87% | ▲ +1.73% | $11.44 (−0.87%) |
|
May 29, 2026
8d ago
|
6-K
| $9.81 $10.59 | ▲ +7.95% | ▲ +7.68% | $11.44 (+16.62%) |
|
May 28, 2026
9d ago
|
Press Release
| $10.55 $9.81 | ▼ −7.01% | ▼ −7.26% | $11.44 (+8.44%) |
|
Mar 16, 2026
11w ago
|
Press Release
| $4.32 $4.62 | ▲ +6.94% | ▲ +6.67% | $11.44 (+164.81%) |
|
Mar 12, 2026
12w ago
|
Press Release
| $4.73 $4.36 | ▼ −7.82% | ▼ −7.22% | $11.44 (+141.86%) |
|
Mar 10, 2026
12w ago
|
Press Release
| $4.02 $3.85 | ▼ −4.23% | ▼ −4.12% | $11.44 (+184.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access